Home
Account
Research Tools & Data
Educate
Contribute
News
ETFs
Sectors
About
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Economic Calendar
Chart School
Tutorials
Learning Center
Submit Article
Join Blog Network
Chat Rooms
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Terms and Conditions
Enter Symbol
Overview
Community Research
Stock Sentiment
Whisper Estimates
Enter Estimates
Company Profile
Technical Charts
Competitors
Analyst Ratings
Analyst Estimates
Sales Estimates
Related News
Blog Articles
Press Releases
Message Board
Option Chain
Financial Ratios
Technicals
SEC Filings
Press Releases
OXiGENE to Acquire VaxGen in a Stock-for-Stock Merger
Trial: HIV vaccine 31 percent effective
The VaxGen Full Value Committee Nominates Five Highly Qualified Candidates to Replace Current VaxGen Board
VaxGen Provides Financial Update Following the Filing of Its 10-Q for Second Quarter With SEC; Results Include $8.5 Million Charge in Respect of Manufacturing Plant Asset Impairment
VaxGen Receives Repayment in Full of Bridge Loan to Raven biotechnologies
VaxGen Restructures Board of Directors - May 26 2008 10:31PM
Vaxgen Files 10-Q for First Quarter With SEC, Provides Future Burn Rate Guidance - May 27 2008 12:53AM
VaxGen Sells Anthrax Vaccine Program and Related Assets and Technology to Emergent BioSolutions, Inc. - Jun 2 2008 2:18AM
VaxGen Restructures Following Termination of Proposed Merger
Fundamental data is provided by
Zacks Investment Research
, market data is provided by
AlphaTrade.
, and Commentary and Press Releases provided by
Quotemedia
